Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Waldenstrom Macroglobulinemia × Dexamethasone × Clear all

Phase

Phase 2 21 Phase 1 3 Phase 3 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Multiple Myeloma 8 Leukemia 5 Neoplasms, Plasma Cell 2 Lung Neoplasms 2 Leukemia, T-Cell 2 Carcinoma, Non-Small-Cell Lung 2 Waldenstrom Macroglobulinemia 1 Vomiting 1 Uterine Cervical Neoplasms 1 Recurrence 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Neoplasm Metastasis 1 Mouth Neoplasms 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Fatigue 1 Burkitt Lymphoma 1 Breast Neoplasms 1 Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 2 ibrutinib 1 fludarabine phosphate 1 Whole-Body Irradiation 1 Thiotepa 1 Rituximab 1 Melphalan 1 Etoposide 1 Dexamethasone 1 Carboplatin 1 Busulfan 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04061512 2024-05-10

RAINBOW

University College, London

Phase 2/3 Recruiting

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡